Teva's Huntington's Rejection May Be Neurocrine's Good Fortune

01 Jun 2016

• By Donna Young

Teva Pharmaceutical Industries Ltd.'s bad luck in getting its experimental Huntington's disease drug deutetrabenazine (SD-809) across the FDA's finish line may be Neurocrine Bioscience's good fortune for its investigational agent valbenazine in another indication – tardive dyskinesia, a condition for which both companies are expected to file applications for their respective products in the US.

The FDA's rejection on May 31 of Teva Pharmaceutical Industries Ltd.'s new drug application (NDA) for its experimental Huntington disease drug deutetrabenazine (SD-809) may be Neurocrine Biosciences Inc.'s good fortune in another indication – tardive dyskinesia (TD), a disease for which the two companies may end up competing against each other.

Teva's bad luck had shares of Neurocrine jumping more than 10% on May 31, before closing at $41.65, up $3.46,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

04 Jul 2025

• By Joseph Haas

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

04 Jul 2025

• By Jessica Merrill

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

04 Jul 2025

• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

04 Jul 2025

• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

04 Jul 2025

• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.